September 13, 2016
1 min read
Save

Study: Risk stratification protocol reduced rate of postoperative aggressive anticoagulation

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Recently published results showed 70% of patients who underwent total hip or knee arthroplasty avoided more aggressive anticoagulation after the use of a risk stratification protocol for venous thromboembolism.

Researchers stratified 3,143 patients undergoing primary or revision knee or hip arthroplasty to either a routine risk (70.7%) or high risk (29.3%) venous thromboembolism (VTE) thromboprophylaxis regimen. Patients in the routine-risk group utilized a mobile compression device for 10 days and received aspirin twice daily for 6 weeks, and patients in the high-risk group received warfarin for 4 weeks and compression stockings for 6 weeks, according to researchers.

Within 6 weeks postoperatively, results showed the routine-risk cohort had a cumulative rate of VTE events of 0.7% vs. 0.5% in the high-risk cohort. Within 6 months postoperatively, the symptomatic VTE risk was 0.6% in the routine-risk cohort and 1.1% in the high-risk cohort, according to results.

Researchers found patients in the routine-risk cohort had a significantly lower rate of major bleeding and incidence of wound complications at 2 weeks. The routine-risk cohort also had a significantly lower risk of incisional draining lasting more than 3 days, results showed. At 2 weeks and 6 weeks postoperatively, researchers noted superior patient satisfaction scores among the routine-risk cohort vs. the high-risk cohort. – by Casey Tingle

 

Disclosures: Nam reports he is a paid consultant for KCI, has stock or stock options in OrthAlign Inc. and receives research support from EOS. Please see the full study for a list of all other authors’ relevant financial disclosures.